Evotec

Name

Evotec

Legal name

Evotec SE

Website

https://evotec.com

Company type

Public

Founded year

1993

Operating status

Operating

Headcount range

5,001–10,000 employees

Ownership category

akta.pro rank

Product category

Drug Discovery and Preclinical Development Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

DMPK / ADME & Bioanalysis (HLAGAFAC)

akta.pro secondary industries

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), Impurity / Reference Standard Synthesis & Characterization (HLAGAHAG), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines) (HLACAOAO)

Keywords

• Contract research services
• Drug discovery platform
• Biologics manufacturing
• Preclinical development services
• ADME-Tox solutions

Headquarters

HQ city

Hamburg

HQ country

Germany

HQ region

Europe

Offices10 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. EVT Execute (Fee-for-Service Contract Research): Fee-for-service contract research generating recurring revenue from multi-year alliances with pharmaceutical and biotech partners, providing CRO essentials and integrated drug discovery services. Stable revenue stream from research partnerships.
2. EVT Innovate (Co-developed Proprietary Projects): Co-developed proprietary projects generating revenue through upfront fees, research milestones, development milestones, and royalties on successful products. Includes over 100 proprietary R&D assets, most being co-owned.
3. Milestone payments from collaborations: Milestone-based revenue from major partnerships including Bristol Myers Squibb protein degradation ($10M, $5M, $25M+ milestones), BMS neuroscience ($25M milestones), Bayer, Pfizer, and others. Strategic transaction with Sandoz includes payments potentially exceeding US$650M plus royalties.
4. Biologics CDMO services (Just - Evotec Biologics): Contract development and manufacturing organization (CDMO) services for biologics, including continuous biomanufacturing via J.POD technology. Includes US Department of Defense, BARDA and Gates Foundation contracts.
5. Royalty income on partnered products: Royalties on successful partnered products and licensing income, including royalties on portfolio of up to 10 biosimilar molecules from Sandoz transaction.
6. Equity upside from portfolio companies: Revenue from equity stakes in portfolio companies such as Tubulis (3.14% equity stake yielding ~$100M from Gilead acquisition), Dark Blue Therapeutics (~20% equity stake yielding value from Amgen acquisition), and Breakpoint Therapeutics.

Pricing tiers

Go-to-market motion1 record

Distribution channels8 records

Marketing channels11 records

Core offering

Evotec is a drug discovery and preclinical development company providing fully integrated R&D services across small molecules, biologics, and cell therapies through proprietary AI/ML-enabled platforms (PanOmics, PanHunter, Molecular Patient Databases, iPSC disease modeling). The company operates three business pillars: Discovery & Preclinical Development (CRO services), Just - Evotec Biologics (biologics design and continuous manufacturing via J.POD, J.MD, J.CHO platforms), and Cyprotex (specialist ADME-Tox solutions), serving pharma, biotech, government and academic partners under flexible fee-for-service and co-development partnership models.

Product overview

Evotec operates a single integrated platform-plus-modules architecture: a unified end-to-end drug discovery and preclinical development engine delivered through three principal business pillars — Discovery & Preclinical Development (the core CRO platform offering CRO Essentials and integrated services), Just – Evotec Biologics (the Seattle-based biologics CDMO subsidiary with its J.POD® manufacturing technology, J.MD™ AI molecular design platform, and J.CHO™ high expression system), and Cyprotex (the specialist ADME-Tox subsidiary with unique assay platforms including eCiphr®Cardio, eCiphr®Neuro, CellCiphr® Premier, and 3D Microtissue models). Layered across these pillars are proprietary next-generation technology platforms — PanOmics, PanHunter (which integrates with QIAGEN's OmicSoft Land Databases), Molecular Patient Databases, and iPSC-based disease modeling — supporting work across multiple therapeutic modalities (small molecules, biologics, and cell therapies including the EVO Cells platform). The portfolio is organized commercially through a dual-segment model — EVT Execute (fee-for-service contract research) and EVT Innovate (co-developed proprietary projects) — and is undergoing the Horizon strategic transformation to refocus the global footprint and operating model. Therapeutic areas covered include oncology, cardiovascular and metabolic diseases, neurology, and immunology.

Differentiator

Problem solved

Functional benefit

Brands

• Cyprotex: Evotec's specialist for ADME-Tox solutions, providing high-quality in vitro and in silico services that enhance the safety and success of drug candidates.
• Just – Evotec Biologics
• Evotec Forschung

Products and services

• Discovery & Preclinical Development Services

Quantifiable outcome

• €788.4 million full year 2025 revenue
• +9 more outcomes

Named customers36 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability11 records

Feature12 records

Partnerships

26 partnerships are on record, tiered flagship, core and minor.

• Gilead SciencesflagshipStrategic or Co-development Partner · 7 April 2026Gilead's acquisition of Tubulis GmbH for $3.15 billion in upfront cash plus $1.85 billion contingent milestone payments, benefiting Evotec via its 3.14% equity stake in Tubulis (~ $100M upfront). TUB-040 antibody-drug conjugate targeting ovarian cancer.
• BARDA (Biomedical Advanced Research and Development Authority)coreStrategic or Co-development Partner · 23 March 2026BioMaP-Consortium selection of Just - Evotec Biologics for manufacturing optimization of monoclonal antibody cocktail targeting Ebola virus and Sudan virus; multi-year program with potential award up to $10M if all options activated. Part of broader US government medical countermeasure partnership.
• Amgen Inc.coreStrategic or Co-development Partner · 8 January 2026Amgen's acquisition of Dark Blue Therapeutics (Oxford-based) for up to US$840M; benefits Evotec via its ~20% equity stake earned through Academic BRIDGE programme. Evotec to receive portion of upfront payment and potential additional upside from defined development milestones.
• Sandoz AGflagshipOEM/ Whitelabel/ Licensing Partner · 5 December 2025Sale of Just - Evotec Biologics EU SAS Toulouse site plus indefinite technology license to Evotec's continuous manufacturing platform technology. Potential payments may exceed US$650M plus royalties on portfolio of up to 10 biosimilar molecules, of which six have originator net sales value of US$90bn. All JEB SAS employees joined Sandoz.
• NURTuRE-AKI ConsortiumminorStrategic or Co-development Partner · 25 June 2025Joined consortium to gain multi-omics-based molecular understanding of acute kidney injury (AKI) via patient cohort.
• Boehringer IngelheimcoreStrategic or Co-development Partner · 3 June 2025Co-founding partner (with bioMérieux and Evotec) of Aurobac Therapeutics, a biopharmaceutical company targeting antimicrobial resistance (AMR) for hospital-acquired infections and sepsis.
• Yonsei University & Zymedi (Korea)minorStrategic or Co-development Partner · 22 January 2025KIAT grant-funded collaboration to develop first-in-class biologic therapies to treat lung diseases, including asthma and idiopathic pulmonary fibrosis (IPF); $4.5M grant from Korea Institute of Advanced Technology.
• LAB eN² Academic Partners (Boston University, Harvard/Mass General Brigham, Joslin Diabetes Center)minorStrategic or Co-development Partner · 11 December 2024First three projects selected for LAB eN² drug discovery accelerator with Novo Nordisk; translational drug discovery program aimed at converting academic research into novel therapeutics.
• Novo NordiskflagshipStrategic or Co-development Partner · 26 September 2024LAB eN² translational drug discovery accelerator selected first three projects (Boston University, Harvard/Mass General Brigham, Joslin Diabetes Center). Technology development partnership for next generation cell therapies announced September 2024.
• X-ChemcoreTechnology or Integration · 5 September 2024Collaboration agreement using DNA-encoded library (DEL) technology to accelerate early-stage drug discovery.
• PfizerflagshipStrategic or Co-development Partner · 10 July 2024Multi-year master research collaboration and option and license agreement focused on early discovery research for metabolic and infectious diseases in France. Part of broader strategic pharma partner network.
• U.S. Department of Defense (DOD)coreStrategic or Co-development Partner · 25 June 2024Manufacturing Optimization Program for accelerated monoclonal antibody development and manufacturing solution for biologics medical countermeasures. Multi-year program award valued up to $39M.
• University of Bristol (beLAB1407 BRIDGE)minorStrategic or Co-development Partner · 24 June 2024Award within beLAB1407 BRIDGE partnership to develop novel antisense oligonucleotide (ASO) based treatment for atherosclerosis, the leading cause of cardiovascular diseases.
• QIAGENcoreTechnology or Integration · 3 June 2024Software collaboration to leverage QIAGEN's OmicSoft Land Databases through Evotec's PanOmics data access and analysis platform PanHunter. Combines comprehensive datasets with advanced analytics capabilities.
• Aurobac Therapeutics (with Boehringer Ingelheim and bioMérieux)coreStrategic or Co-development Partner · 3 June 2024Joint venture addressing antimicrobial resistance (AMR); new development program with Boehringer Ingelheim for hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), and sepsis.
• bioMérieuxcoreStrategic or Co-development Partner · 3 June 2024Co-founding partner (with Boehringer Ingelheim and Evotec) of Aurobac Therapeutics; bioMérieux contributes diagnostic strategies for patient stratification and optimization of treatment outcomes.
• Inserm, Lille University Hospital, Inserm TransfertcoreStrategic or Co-development Partner · 30 May 2024Partnership to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases.
• CHDI Foundation, Inc.flagshipStrategic or Co-development Partner · 28 May 2024Extended 20-year strategic drug discovery collaboration in Huntington's disease. Collaboration advances fundamental scientific understanding of the disease and supports development of new effective treatments.
• Bayer AGflagshipStrategic or Co-development Partner · 30 April 2024Multi-target research collaboration in kidney diseases and precision cardiology. Bayer initiated Phase 2 study of BAY 3401016 (Sema3A monoclonal antibody) for Alport syndrome in December 2025, with milestone payment expected early 2026. Strategic collaboration focuses on innovative precision treatments for cardiovascular diseases.
• Variant BiocoreStrategic or Co-development Partner · 18 April 2024Strategic partnership to discover and develop best-in-class treatments for fibrotic diseases using Variant Bio's genomics platform.
• Claris VenturesminorStrategic or Co-development Partner · 6 March 2024Framework agreement to accelerate programmes from Claris Ventures' portfolio companies into the clinic using Evotec's fully integrated platform.
• Crohn's & Colitis FoundationminorStrategic or Co-development Partner · 10 January 2024Agreement to promote drug discovery for new IBD therapies including Crohn's disease and ulcerative colitis.
• OwkincoreStrategic or Co-development Partner · 4 January 2024AI-powered multi-target strategic partnership to accelerate therapeutics pipeline in oncology, immunology and inflammation (I&I). French-American Techbio company collaboration.
• Bill & Melinda Gates FoundationflagshipStrategic or Co-development Partner · 19 December 2023Multiple major grants and long-term collaboration: $2.5M for iPSC-derived teratogenicity platform; $6.6M for TB drug discovery; $18M for women's health and contraceptive technology; $9.9M combined for TB research (2025); $4.9M + $5M for TB drug discovery (April 2026). J.MD molecular design partnership extends 2014 partnership producing GMP manufacturing campaigns for RSV, Malaria, HIV monoclonal antibodies.
• Almirall S.A.coreStrategic or Co-development Partner · 1 May 2022Multi-target drug discovery alliance in medical dermatology. Nominated first small molecule preclinical development candidate (PDC) for immune-mediated inflammatory skin diseases in May 2026. Success-based milestones potentially worth up to €230 million per program plus royalties on net sales in high single-digit percentage range.
• Bristol Myers Squibb (BMS)flagshipStrategic or Co-development Partner · 1 January 2018Multi-decade strategic partnership spanning protein degradation (CELMoD molecular glues) and neuroscience/neurodegenerative diseases. Combined Evotec's PanOmics and PanHunter platforms with BMS's CELMoD agent library. Major milestones include $10M for Phase 1 BMS-986506 study initiation in clear cell renal cell carcinoma, $25M for neuroscience progress, $5M for IND acceptance, $75M total in 2024 progress payments.

Scale indicators15 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Charles River Laboratories: Global CRO/CDMO offering discovery and safety assessment services, preclinical research, and biologics manufacturing — directly competes with Evotec's integrated drug discovery, Cyprotex ADME-Tox, and Just – Evotec Biologics offerings across the same pharma and biotech customer base.
• WuXi AppTec: China-headquartered CRO/CDMO providing end-to-end discovery, preclinical, and biologics manufacturing services to global pharma — the most direct large-scale competitor to Evotec's integrated drug discovery and biologics CDMO franchise, particularly in early discovery and biologics manufacturing.
• Catalent (Novo Holdings): US-based biologics CDMO and drug delivery specialist recently acquired by Novo Holdings — competes directly with Just – Evotec Biologics in clinical and commercial biologics manufacturing, particularly for monoclonal antibodies and complex modalities.
• Samsung Biologics: South Korea-headquartered biologics CDMO with large-scale mammalian cell culture capacity — directly competes with Just – Evotec Biologics in contract manufacturing of monoclonal antibodies and biosimilars for global pharma clients.
• WuXi Biologics: Global biologics CDMO providing end-to-end development and manufacturing services — one of the largest direct competitors to Just – Evotec Biologics in antibody and recombinant protein manufacturing, with similar end-to-end service positioning.

Broad incumbents

• IQVIA: Largest global CRO with broader clinical and commercial services; competes with Evotec in early discovery and technology-enabled R&D services, though its core franchise is late-stage clinical and real-world data rather than preclinical discovery.
• Lonza Group: Swiss-listed global CDMO leader for biologics, cell and gene therapies, and small molecules — competes directly with Just – Evotec Biologics in mammalian cell culture and with Evotec more broadly in end-to-end biologics development and manufacturing.
• ICON plc: Major global CRO providing clinical and consulting services to pharma/biotech — broader clinical focus, but overlaps with Evotec in integrated R&D partnerships and competes for the same large pharma outsourcing budgets.

Emerging players

• Schrödinger: AI-driven computational drug discovery platform with software and co-owned pipeline assets — directly comparable to Evotec's AI/ML-enabled discovery platform thesis (PanOmics, J.MD) and overlaps in structure-based design and partnered drug discovery.
• Certara: Biosimulation and model-informed drug development software and services company — adjacent to Evotec's modeling & simulation capabilities and competing for pharma R&D technology budgets, particularly in PK/PD and regulatory submissions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/evotec
• Xx.com/evotec

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries7 records

Funding overview

Funding rounds19 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A16 records

Investments28 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evotec